ORIC Pharmaceuticals presented data from its Phase 1b trial of rinzimetostat in metastatic castration-resistant prostate cancer, demonstrating a 55% prostate-specific antigen decline of at least 50% (PSA50) and a 20% PSA90 rate when dosed in combination with standard androgen receptor inhibitors. Additionally, circulating tumor DNA clearance was observed in 59% of patients, suggesting robust target engagement and potential disease control in a heavily pretreated population. The safety profile was differentiated, with most treatment-related adverse events being Grade 1 or 2 and no unexpected toxicities reported, supporting further development of rinzimetostat as a best-in-class PRC2 inhibitor in prostate cancer.

In an investigator-led expansion cohort, ORIC’s oral EGFR exon 20 inhibitor enozertinib achieved an overall response rate of 67% in first-line patients and a 100% intracranial response rate among those with measurable central nervous system disease. These data underscore enozertinib’s ability to penetrate the blood–brain barrier and deliver deep, durable responses in a patient subset with limited targeted therapy options. Safety findings were consistent with known class effects, with low incidence of Grade 3 pneumonitis and manageable dermatologic events.

During 2025, ORIC added key executives with extensive oncology development and commercial experience to its leadership team, enhancing capabilities in late-stage trial execution and global regulatory strategy. Concurrent with data announcements, the company bolstered its balance sheet, extending its cash runway into the second half of 2028. This financial position provides sufficient capital to advance both rinzimetostat and enozertinib through pivotal studies without near-term funding needs, reducing dilution risk for existing investors.

ORIC plans to present combination dose-optimization results for rinzimetostat in the first quarter of 2026 and to initiate its first global Phase 3 registrational trial in metastatic castration-resistant prostate cancer in the first half of 2026. The registrational study, designed in consultation with health authorities, will evaluate overall survival and radiographic progression-free survival as co-primary endpoints, positioning ORIC to potentially file for approval by late 2028. Parallel development of enozertinib is expected to enter pivotal testing by year-end 2026, targeting accelerated pathways in EGFR exon 20-mutant non-small cell lung cancer.